Stockreport

bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF – Majority of patients in the Phase 3 Northstar-2 (HGB-207) study show higher in vivo vector copy numbers and hemoglobin levels; 5/6 patients producing 6 [Read more]